bioRxiv Science⌕ Search

Biology subjects

Byun, J. M.

Publications and source records attributed to Byun, J. M..

3 recordsLinked to original sources

Sequencing analysis of Helicobacter pylori infection in gastric mucosa and its progression to gastric mucosa-associated tissue (MALT) lymphoma

IntroductionThe pathogenesis of gastric mucosa-associated tissue (MALT) lymphoma is associated with Helicobacter pylori infection. Although treatment strategies and responsiveness according to the stage of gastric MALT lymphoma have been widely reported, a detailed study of the biological carcinogenic process is still required. MethodPaired, fresh tumor-adjacent normal and gastric mucosal tissue samples from 13 patients with gastric MALT lymphoma were prospectively collected. Whole exome sequencing (WES) and whole-transcriptome sequencing (WTS) data were generated. The analysis of mutations, gene fusion, gene expression, and the microbiome was stratified by H. pylori infection and disease status. ResultsSomatic mutations in TRAF3 and TNFAIP3 were identified in H. pylori-negative gastric MALT lymphoma. Fusions involving BIRC3-MALT1 (2 samples) and TBL1XR1-TP63 (1 sample with H. pylori infection) were detected. Stepwise comparative analysis of RNA expression revealed upregulation of immune response, inflammatory responses, and the NF- {kappa}B signaling pathway in H. pylori-positive MALT lymphoma cases. Pathways associated with pathogens were upregulated in H. pylori-negative MALT lymphoma cases, suggesting that infections other than H. pylori may affect lymphomagenesis. Microbiome analysis revealed that genus_Rothia was negatively correlated with alpha diversity. ConclusionA stepwise approach using diverse stages of WTS data revealed detailed pathogenic mechanisms of gastric MALT lymphoma. Chronic inflammation following infection contributes to gastric MALT lymphomagenesis in both H. pylori positive and negative cases.

bioinformatics↗

Predicting the efficacy of BH3 mimetics through the profiling of multiple protein complexes

BH3 mimetics are protein-protein interaction (PPI) inhibitors that saturate anti-apoptotic proteins in the BCL2 family to induce apoptosis in cancer cells, a prominent example of protein complex-targeting therapies. Despite the remarkable success of the BH3 mimetic ABT-199 in treating hematological malignancies, only a fraction of patients respond to ABT-199 and eventually develop resistance, necessitating the predictive biomarkers for both initial responses and resistance development. We here used the single-molecule pull-down and co-immunoprecipitation platform to quantify more than 20 different types of PPI complexes using [~]1.2x106 cells in total, revealing the rewired status of the BCL2 family PPI network. By comparing the obtained multi-dimensional data with BH3 mimetic efficacies determined ex vivo, we constructed an analysis model for ABT-199 efficacy that designates the BCL2-BAX and BCLxL-BAK complexes as the primary mediators of drug effectiveness and resistance. We then applied this model to assist in therapeutic decision-making for acute myeloid leukemia patients in a prospective manner. Our work demonstrates a capability for the extensive characterization of PPI complexes in clinical specimens, potentially opening a new avenue of precision medicine for protein complex-targeting therapies.

molecular biology↗